focus -WSS

focus

author：Wikipedia 2025-09-27 22:48:52 - browse：78

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Congress gives doctors Medicare pay bump

entertainment

WSS

What STAT readers think about the FDA and patient advocacy

Change Healthcare cyberattack outage could last weeks

Kenai launches with $82 million for Parkinson’s stem cell therapy

SEC charges former device maker CEO with $41 million fraud

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

AstraZeneca loses challenge to Medicare drug price negotiation

entertainment

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

ALS groups 'won't be played again' by the FDA, drug sponsors

After affirmative action ruling, medical educators look to 'holistic review'

How to address the problem of discarded donor organs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Anesthesiologist group: stop taking Ozempic before surgery

Obesity now affects over 1 billion people worldwide, study finds

Drug repurposing or repositioning? The language matters

In Spain, a hospital brews its own CAR

entertainment

AstraZeneca loses challenge to Medicare drug price negotiation

Covid isolation guidance eased by the CDC

Can sheer will power keep patients alive in their dying hours?

Editas, Vertex strike deal on CRISPR

In Spain, a hospital brews its own CAR

Scientists unlock the key to scar

knowledge

focus

entertainment

leisure time